{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:26Z","timestamp":1793370806456,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.fr","clinicalkey.jp","jprasopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JPRAS Open"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jpra.2026.09.019","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:50:53Z","timestamp":1789746653000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TrenibotulinumtoxinE: Pharmacology, clinical evidence, and emerging role in aesthetic medicine"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-0116","authenticated-orcid":false,"given":"Chaocheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3838-6768","authenticated-orcid":false,"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-4746","authenticated-orcid":false,"given":"Alain","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpra.2026.09.019_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2020_351","article-title":"Novel native and engineered botulinum neurotoxins","volume":"263","author":"Steward","year":"2021","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.jpra.2026.09.019_bib0002","doi-asserted-by":"crossref","first-page":"NP218","DOI":"10.1093\/asj\/sjab358","article-title":"Facial aesthetic priorities and concerns: a physician and patient perception Global Survey","volume":"42","author":"Fabi","year":"2022","journal-title":"Aesthet Surg J."},{"issue":"1","key":"10.1016\/j.jpra.2026.09.019_bib0003","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jocd.15513","article-title":"Botulinum toxin for cosmetic treatments in young adults: an evidence-based review and survey on current practice among aesthetic practitioners","volume":"22","author":"Michon","year":"2023","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.jpra.2026.09.019_bib0004","unstructured":"Aesthetics, A. Allergan Aesthetics receives approval for Boey\u00ae (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients [press release]. Available from: abbVie News Center reports findings from Holistic Beauty Global Research, REF-148616, January 2026. Jan 2026."},{"issue":"3","key":"10.1016\/j.jpra.2026.09.019_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","article-title":"Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans","volume":"256","author":"Eleopra","year":"1998","journal-title":"Neurosci Lett."},{"issue":"4","key":"10.1016\/j.jpra.2026.09.019_bib0006","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1044-7431(02)00016-7","article-title":"Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation","volume":"22","author":"Meunier","year":"2003","journal-title":"Mol Cell Neurosci."},{"key":"10.1016\/j.jpra.2026.09.019_bib0007","article-title":"Evaluation of botulinum neurotoxin type E preparation (trenibotulinumtoxinE) in the mouse digit abduction score (DAS) assay","volume":"237","author":"Canty GSN","year":"2024","journal-title":"Toxicon."},{"key":"10.1016\/j.jpra.2026.09.019_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/toxins17050230","article-title":"Preclinical evaluation of botulinum toxin type E (TrenibotulinumtoxinE) using the mouse digit abduction score (DAS) assay","volume":"17","author":"Nicholson","year":"2025","journal-title":"Toxins (Basel)."},{"key":"10.1016\/j.jpra.2026.09.019_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/toxins10070268","article-title":"Light chain diversity among the botulinum neurotoxins","volume":"10","author":"Gardner","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"9","key":"10.1016\/j.jpra.2026.09.019_bib0010","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1073\/pnas.0400229101","article-title":"Plasma membrane localization signals in the light chain of botulinum neurotoxin","volume":"101","author":"Fernandez-Salas","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"26","key":"10.1016\/j.jpra.2026.09.019_bib0011","doi-asserted-by":"crossref","first-page":"E5158","DOI":"10.1073\/pnas.1621076114","article-title":"Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication","volume":"114","author":"Tsai","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"Pt 15","key":"10.1016\/j.jpra.2026.09.019_bib0012","first-page":"3294","article-title":"Recruitment of septin cytoskeletal proteins by botulinum toxin A protease determines its remarkable stability","volume":"127","author":"Vagin","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jpra.2026.09.019_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins14010014","article-title":"Structural analysis of botulinum neurotoxins type B and E by Cryo-EM","volume":"14","author":"Kosenina","year":"2021","journal-title":"Toxins (Basel)."},{"issue":"1","key":"10.1016\/j.jpra.2026.09.019_bib0014","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/s41467-023-37860-8","article-title":"Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jpra.2026.09.019_bib0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","article-title":"Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation","volume":"386","author":"Kumaran","year":"2009","journal-title":"J Mol Biol."},{"issue":"2","key":"10.1016\/j.jpra.2026.09.019_bib0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0928-4257(98)80151-4","article-title":"On the action of botulinum neurotoxins A and E at cholinergic terminals","volume":"92","author":"Washbourne","year":"1998","journal-title":"J Physiol Paris."},{"issue":"3","key":"10.1016\/j.jpra.2026.09.019_bib0017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","article-title":"Botulinal neurotoxins: revival of an old killer","volume":"5","author":"Montecucco","year":"2005","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"10.1016\/j.jpra.2026.09.019_bib0018","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tibs.2005.05.002","article-title":"SNARE complexes and neuroexocytosis: how many, how close?","volume":"30","author":"Montecucco","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jpra.2026.09.019_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/toxins16050225","article-title":"Intramuscular botulinum neurotoxin serotypes E and A elicit distinct effects on SNAP25 protein fragments, muscular histology, spread and neuronal transport: an integrated histology-based study in the rat","volume":"16","author":"Martin","year":"2024","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.jpra.2026.09.019_bib0020","article-title":"Diffusion of botulinum toxins","volume":"2","author":"Brodsky","year":"2012","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"6","key":"10.1016\/j.jpra.2026.09.019_bib0021","doi-asserted-by":"crossref","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","article-title":"Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study","volume":"142","author":"Yoelin","year":"2018","journal-title":"Plast Reconstr Surg."},{"key":"10.1016\/j.jpra.2026.09.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjag126","article-title":"Safety and efficacy of TrenibotulinumtoxinE for moderate-to-severe glabellar lines: a phase 2b, double-blind, placebo-controlled, dose-escalation study","author":"Lain","year":"2026","journal-title":"Aesthet Surg J."},{"key":"10.1016\/j.jpra.2026.09.019_bib0023","doi-asserted-by":"crossref","unstructured":"Moers-Carpi CB, M., Biesman, B., Hooper, D., Rivkin, A., Chiang, C.-Y.i, Park, G.S., Weitzenfeld, A., Chang-Lin, J.-E.n. Rapid onset and short duration of trenibotulinumtoxinE for treatment of moderate to severe glabellar lines: efficacy and safety results from a phase 3 study. 2026;271.","DOI":"10.1016\/j.toxicon.2025.108815"},{"key":"10.1016\/j.jpra.2026.09.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjag154","article-title":"Rapid results with TrenibotulinumtoxinE for the treatment of glabellar lines in toxin-naive adults: safety, efficacy, and satisfaction findings from a pivotal phase 3 study","author":"Lain","year":"2026","journal-title":"Aesthet Surg J."},{"key":"10.1016\/j.jpra.2026.09.019_bib0025","first-page":"271","article-title":"Sequential administration of trenibotulinumtoxinE and onabotulinumtoxinA for glabellar lines: a phase 1 evaluation","author":"Hanke JK-J","year":"2026","journal-title":"Toxicon"},{"key":"10.1016\/j.jpra.2026.09.019_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108913","article-title":"Integrated immunogenicity assessment of a novel, first-in-class trenibotulinumtoxinE across 5 clinical trials for glabellar lines","volume":"271","author":"Yoelin EL","year":"2026","journal-title":"Toxicon"},{"key":"10.1016\/j.jpra.2026.09.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108946","article-title":"Beyond structural divergence: multiscale computational immunogenicity modelling of botulinum neurotoxin E and cross-reactivity in botulinum neurotoxin A primed hosts","volume":"271","author":"Rahman","year":"2026","journal-title":"Toxicon"}],"container-title":["JPRAS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352587826003414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352587826003414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:56:51Z","timestamp":1793368611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352587826003414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"alternative-id":["S2352587826003414"],"URL":"https:\/\/doi.org\/10.1016\/j.jpra.2026.09.019","relation":{},"ISSN":["2352-5878"],"issn-type":[{"value":"2352-5878","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TrenibotulinumtoxinE: Pharmacology, clinical evidence, and emerging role in aesthetic medicine","name":"articletitle","label":"Article Title"},{"value":"JPRAS Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpra.2026.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.","name":"copyright","label":"Copyright"}]}}